Total Payments
$47,715
2023 Payments
$5,519
Companies
5
Transactions
13
Medicare Patients
1,935
Medicare Billing
$218,980
Payment Breakdown by Category
Consulting$47,431 (99.4%)
Food & Beverage$284.22 (0.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $47,431 | 10 | 99.4% |
| Food and Beverage | $284.22 | 3 | 0.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Myovant Sciences Inc. | $41,913 | 7 | $0 (2021) |
| Sumitomo Pharma America, Inc. | $5,519 | 3 | $0 (2023) |
| Genentech, Inc. | $149.68 | 1 | $0 (2018) |
| Medtronic MiniMed, Inc. | $123.15 | 1 | $0 (2018) |
| Janssen Pharmaceuticals, Inc | $11.39 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $5,519 | 3 | Sumitomo Pharma America, Inc. ($5,519) |
| 2021 | $41,913 | 7 | Myovant Sciences Inc. ($41,913) |
| 2018 | $272.83 | 2 | Genentech, Inc. ($149.68) |
| 2017 | $11.39 | 1 | Janssen Pharmaceuticals, Inc ($11.39) |
All Payment Transactions
13 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/09/2023 | Sumitomo Pharma America, Inc. | — | Consulting Fee | Cash or cash equivalent | $790.00 | General |
| 10/26/2023 | Sumitomo Pharma America, Inc. | — | Consulting Fee | Cash or cash equivalent | $3,258.75 | General |
| 10/19/2023 | Sumitomo Pharma America, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,470.00 | General |
| 09/08/2021 | Myovant Sciences Inc. | — | Consulting Fee | Cash or cash equivalent | $1,400.00 | General |
| 08/11/2021 | Myovant Sciences Inc. | — | Consulting Fee | Cash or cash equivalent | $3,062.50 | General |
| 07/14/2021 | Myovant Sciences Inc. | — | Consulting Fee | Cash or cash equivalent | $5,425.00 | General |
| 06/10/2021 | Myovant Sciences Inc. | — | Consulting Fee | Cash or cash equivalent | $7,700.00 | General |
| 05/12/2021 | Myovant Sciences Inc. | — | Consulting Fee | Cash or cash equivalent | $7,350.00 | General |
| 04/07/2021 | Myovant Sciences Inc. | — | Consulting Fee | Cash or cash equivalent | $6,650.00 | General |
| 02/10/2021 | Myovant Sciences Inc. | ORGOVYX (Drug) | Consulting Fee | Cash or cash equivalent | $10,325.00 | General |
| Category: HORMONE THERAPY | ||||||
| 06/02/2018 | Genentech, Inc. | — | Food and Beverage | In-kind items and services | $149.68 | General |
| 03/27/2018 | Medtronic MiniMed, Inc. | Minimed 670G System (Device) | Food and Beverage | In-kind items and services | $123.15 | General |
| Category: Durable Pump | ||||||
| 08/09/2017 | Janssen Pharmaceuticals, Inc | INVOKANA (Drug) | Food and Beverage | In-kind items and services | $11.39 | General |
| Category: Cardiovascular & Metabolism | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 530 | 840 | $270,838 | $62,848 |
| 2022 | 6 | 464 | 733 | $229,007 | $55,962 |
| 2021 | 9 | 498 | 784 | $297,696 | $64,571 |
| 2020 | 9 | 443 | 620 | $187,327 | $35,599 |
Total Patients
1,935
Total Services
2,977
Medicare Billing
$218,980
Procedure Codes
30
All Medicare Procedures & Services
30 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 352 | 577 | $199,120 | $43,970 | 22.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 38 | 38 | $9,652 | $5,891 | 61.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 32 | 42 | $17,649 | $4,727 | 26.8% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2023 | 41 | 106 | $25,864 | $3,021 | 11.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 27 | 27 | $4,914 | $2,685 | 54.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 40 | 50 | $13,639 | $2,554 | 18.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 301 | 499 | $155,340 | $38,546 | 24.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 36 | 48 | $18,164 | $5,553 | 30.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 33 | 33 | $16,632 | $4,530 | 27.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 27 | 27 | $9,114 | $2,927 | 32.1% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2022 | 38 | 91 | $22,204 | $2,761 | 12.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 29 | 35 | $7,553 | $1,645 | 21.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 248 | 451 | $189,712 | $35,718 | 18.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 48 | 76 | $28,356 | $9,716 | 34.3% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 43 | 43 | $24,422 | $7,082 | 29.0% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 50 | 50 | $23,500 | $5,350 | 22.8% |
| 95251 | Ambulatory continuous glucose (sugar) including interpretation and report for a minimum of 72 hours | Office | 2021 | 28 | 74 | $18,056 | $2,203 | 12.2% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2021 | 16 | 18 | $3,204 | $1,479 | 46.2% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2021 | 24 | 29 | $3,509 | $1,468 | 41.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 25 | 25 | $5,875 | $1,113 | 18.9% |
| 99441 | Physician telephone patient service, 5-10 minutes of medical discussion | Office | 2021 | 16 | 18 | $1,062 | $442.54 | 41.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 193 | 321 | $125,929 | $18,808 | 14.9% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 69 | 69 | $24,048 | $7,111 | 29.6% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 49 | 64 | $6,884 | $2,808 | 40.8% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 24 | 32 | $4,946 | $2,371 | 47.9% |
About Dr. Elaine Wong, MD
Dr. Elaine Wong, MD is a Endocrinology, Diabetes & Metabolism healthcare provider based in Emeryville, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/09/2007. The National Provider Identifier (NPI) number assigned to this provider is 1932258258.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Elaine Wong, MD has received a total of $47,715 in payments from pharmaceutical and medical device companies, with $5,519 received in 2023. These payments were reported across 13 transactions from 5 companies. The most common payment nature is "Consulting Fee" ($47,431).
As a Medicare-enrolled provider, Wong has provided services to 1,935 Medicare beneficiaries, totaling 2,977 services with total Medicare billing of $218,980. Data is available for 4 years (2020–2023), covering 30 distinct procedure/service records.
Ad
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism
- Location Emeryville, CA
- Active Since 01/09/2007
- Last Updated 04/16/2017
- Taxonomy Code 207RE0101X
- Entity Type Individual
- NPI Number 1932258258
Products in Payments
- ORGOVYX (Drug) $10,325
- Minimed 670G System (Device) $123.15
- INVOKANA (Drug) $11.39
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.